286 related articles for article (PubMed ID: 24338002)
1. Why anti-Bcl-2 clinical trials fail: a solution.
Harazono Y; Nakajima K; Raz A
Cancer Metastasis Rev; 2014 Mar; 33(1):285-94. PubMed ID: 24338002
[TBL] [Abstract][Full Text] [Related]
2. Targeting the B-cell lymphoma/leukemia 2 family in cancer.
Davids MS; Letai A
J Clin Oncol; 2012 Sep; 30(25):3127-35. PubMed ID: 22649144
[TBL] [Abstract][Full Text] [Related]
3. BH3 mimetics to improve cancer therapy; mechanisms and examples.
Zhang L; Ming L; Yu J
Drug Resist Updat; 2007 Dec; 10(6):207-17. PubMed ID: 17921043
[TBL] [Abstract][Full Text] [Related]
4. ABT-737 induces expression of the death receptor 5 and sensitizes human cancer cells to TRAIL-induced apoptosis.
Song JH; Kandasamy K; Kraft AS
J Biol Chem; 2008 Sep; 283(36):25003-13. PubMed ID: 18599488
[TBL] [Abstract][Full Text] [Related]
5. [Effect and significance of BH3-only protein in targeted therapy of
non-small cell lung cancer].
Gao W; Huang W; Liu K
Zhongguo Fei Ai Za Zhi; 2014 Nov; 17(11):819-23. PubMed ID: 25404273
[TBL] [Abstract][Full Text] [Related]
6. Targeting the Bcl-2-regulated apoptosis pathway by BH3 mimetics: a breakthrough in anticancer therapy?
Labi V; Grespi F; Baumgartner F; Villunger A
Cell Death Differ; 2008 Jun; 15(6):977-87. PubMed ID: 18369371
[TBL] [Abstract][Full Text] [Related]
7. Co-Operativity between MYC and BCL-2 Pro-Survival Proteins in Cancer.
Fairlie WD; Lee EF
Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33799592
[TBL] [Abstract][Full Text] [Related]
8. Restoring cancer's death sentence.
Letai A
Cancer Cell; 2006 Nov; 10(5):343-5. PubMed ID: 17097553
[TBL] [Abstract][Full Text] [Related]
9. An inhibitor of Bcl-2 family proteins induces regression of solid tumours.
Oltersdorf T; Elmore SW; Shoemaker AR; Armstrong RC; Augeri DJ; Belli BA; Bruncko M; Deckwerth TL; Dinges J; Hajduk PJ; Joseph MK; Kitada S; Korsmeyer SJ; Kunzer AR; Letai A; Li C; Mitten MJ; Nettesheim DG; Ng S; Nimmer PM; O'Connor JM; Oleksijew A; Petros AM; Reed JC; Shen W; Tahir SK; Thompson CB; Tomaselli KJ; Wang B; Wendt MD; Zhang H; Fesik SW; Rosenberg SH
Nature; 2005 Jun; 435(7042):677-81. PubMed ID: 15902208
[TBL] [Abstract][Full Text] [Related]
10. Bcl-2 inhibitors: small molecules with a big impact on cancer therapy.
Vogler M; Dinsdale D; Dyer MJ; Cohen GM
Cell Death Differ; 2009 Mar; 16(3):360-7. PubMed ID: 18806758
[TBL] [Abstract][Full Text] [Related]
11. The role of galectin-3 in cancer drug resistance.
Fukumori T; Kanayama HO; Raz A
Drug Resist Updat; 2007 Jun; 10(3):101-8. PubMed ID: 17544840
[TBL] [Abstract][Full Text] [Related]
12. Targeting BCL2 in Chronic Lymphocytic Leukemia and Other Hematologic Malignancies.
Yalniz FF; Wierda WG
Drugs; 2019 Aug; 79(12):1287-1304. PubMed ID: 31313099
[TBL] [Abstract][Full Text] [Related]
13. Targeting BCL-2 regulated apoptosis in cancer.
Campbell KJ; Tait SWG
Open Biol; 2018 May; 8(5):. PubMed ID: 29769323
[TBL] [Abstract][Full Text] [Related]
14. Targeting Bcl-2 family proteins in adult T-cell leukemia/lymphoma: in vitro and in vivo effects of the novel Bcl-2 family inhibitor ABT-737.
Ishitsuka K; Kunami N; Katsuya H; Nogami R; Ishikawa C; Yotsumoto F; Tanji H; Mori N; Takeshita M; Miyamoto S; Tamura K
Cancer Lett; 2012 Apr; 317(2):218-25. PubMed ID: 22138435
[TBL] [Abstract][Full Text] [Related]
15. Nuclear export of phosphorylated galectin-3 regulates its antiapoptotic activity in response to chemotherapeutic drugs.
Takenaka Y; Fukumori T; Yoshii T; Oka N; Inohara H; Kim HR; Bresalier RS; Raz A
Mol Cell Biol; 2004 May; 24(10):4395-406. PubMed ID: 15121858
[TBL] [Abstract][Full Text] [Related]
16. Bcl-2 family of proteins as therapeutic targets in genitourinary neoplasms.
Hall C; Troutman SM; Price DK; Figg WD; Kang MH
Clin Genitourin Cancer; 2013 Mar; 11(1):10-9. PubMed ID: 23083798
[TBL] [Abstract][Full Text] [Related]
17. Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy.
Kang MH; Reynolds CP
Clin Cancer Res; 2009 Feb; 15(4):1126-32. PubMed ID: 19228717
[TBL] [Abstract][Full Text] [Related]
18. Bcl-2-regulated apoptosis: mechanism and therapeutic potential.
Adams JM; Cory S
Curr Opin Immunol; 2007 Oct; 19(5):488-96. PubMed ID: 17629468
[TBL] [Abstract][Full Text] [Related]
19. Modulating the bcl-2 family of apoptosis suppressors for potential therapeutic benefit in cancer.
Shore GC; Viallet J
Hematology Am Soc Hematol Educ Program; 2005; ():226-30. PubMed ID: 16304385
[TBL] [Abstract][Full Text] [Related]
20. Overcoming blocks in apoptosis with BH3-mimetic therapy in haematological malignancies.
Khaw SL; Huang DC; Roberts AW
Pathology; 2011 Oct; 43(6):525-35. PubMed ID: 21881535
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
